Matthaios Dimitrios, Balgkouranidou Ioanna, Neanidis Konstantinos, Sofis Andreas, Pikouli Anastasia, Romanidis Konstantinos, Pappa Aglaia, Karamouzis Michael, Zygogianni Anna, Charalampidis Charalampos, Zarogoulidis Paul, Rigas George, Galanis Alex
Department of Oncology, General Hospital of Rhodes, Rhodes, Greece.
Department of Oncology, Democritus University of Thrace, Alexandroupolis, Greece.
J Cancer. 2024 Apr 22;15(11):3254-3271. doi: 10.7150/jca.94109. eCollection 2024.
Temozolomide is an imidazotetrazine with a long history in oncology especially for the high grade malignant glioma and metastatic melanoma. However, last year's new indications for its use are added. Its optimum pharmacodynamic profile, its ability to penetrate the blood-brain barrier, the existence of methylation of MGMT in solid tumors which enhances its efficacy, the identification of new agents that can overcome temozolomide's resistance, the promising role of temozolomide in turning immune cold tumors to hot ones, are leading to expand its use in other solid tumors, giving oncologists an additional tool for the treatment of advanced and aggressive neoplasms.
替莫唑胺是一种咪唑并四嗪，在肿瘤学领域有着悠久的历史，尤其用于治疗高级别恶性胶质瘤和转移性黑色素瘤。然而，去年又增加了其新的使用适应症。其最佳的药效学特征、穿透血脑屏障的能力、实体瘤中MGMT甲基化的存在增强了其疗效、能够克服替莫唑胺耐药性的新药物的发现、替莫唑胺在将免疫冷肿瘤转变为热肿瘤方面的前景作用，正促使其在其他实体瘤中的应用得到扩展，为肿瘤学家提供了一种治疗晚期侵袭性肿瘤的额外工具。
